Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Free Cash Flow (2016 - 2025)

Protalix BioTherapeutics (PLX) has 16 years of Free Cash Flow data on record, last reported at -$4.2 million in Q3 2025.

  • For Q3 2025, Free Cash Flow fell 210.62% year-over-year to -$4.2 million; the TTM value through Sep 2025 reached -$12.1 million, down 261.64%, while the annual FY2024 figure was $7.4 million, 482.61% up from the prior year.
  • Free Cash Flow reached -$4.2 million in Q3 2025 per PLX's latest filing, up from -$5.7 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $6.2 million in Q2 2021 and bottomed at -$10.2 million in Q1 2021.
  • Average Free Cash Flow over 5 years is -$2.5 million, with a median of -$3.6 million recorded in 2024.
  • Peak YoY movement for Free Cash Flow: tumbled 316.46% in 2022, then surged 238.26% in 2023.
  • A 5-year view of Free Cash Flow shows it stood at -$5.5 million in 2021, then soared by 57.74% to -$2.3 million in 2022, then soared by 238.26% to $3.2 million in 2023, then decreased by 3.8% to $3.1 million in 2024, then plummeted by 235.97% to -$4.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Free Cash Flow were -$4.2 million in Q3 2025, -$5.7 million in Q2 2025, and -$5.4 million in Q1 2025.